biostudies-literatureUnknown16(1)Horcajada JPFerrer Internacional, S.A.<h4>Purpose</h4>To design a randomized clinical trial to assess the efficacy and safety of favipiravir in patients with COVID-19 disease with pneumonia.<h4>Methods</h4>A randomized, double blind, placebo-controlled clinical trial of favipiravir in patients with COVID-19 pneumonia was conducted in three Spanish sites. Randomization 1:1 to favipiravir or placebo (in both groups added to the Standard of Care) was performed to treat the patients with COVID-19 pneumonia. The primary endpoint was "time to clinical improvement," measured as an improvement for ≥ two categories on a 7-point WHO ordinal scale in an up to 28 days' time frame.<h4>Results</h4>Forty-four patients were randomized (23 in the favipiravir group and 21 in the placebo group). The median time to clinical improvement was not diPneumonia (Nathan Qld.)3https://www.ebi.ac.uk/biostudies/studies/S-EPMC10894471biostudies-literatureSafety and efficacy of favipiravir in COVID-19 patients with pneumonia. A randomized, double-blind, placebo-controlled study (FAVID).PMC10894471Real MKnobel HCOVID-HJ23 groupPelegrin ICOVID-MAR Research groupGomez-Junyent JFebrer AMCastaneda-Espinosa SMontero MMAldonza RBrianso SSorli LBarrientos AGomez-Zorrilla SLopez-Montesinos IGuerri-Fernandez RArrieta-Aldea IAlibalic ATarrago CSanchez-Martinez FCamaron JHorcajada JPFernandez ABertran LCanas-Ruano EVillar-Garcia JAuguet-Quintilla TDuran-Taberna MSendra EArenas-Miras MfalseSafety and efficacy of favipiravir in COVID-19 patients with pneumonia. A randomized, double-blind, placebo-controlled study (FAVID).<h4>Purpose</h4>To design a randomized clinical trial to assess the efficacy and safety of favipiravir in patients with COVID-19 disease with pneumonia.<h4>Methods</h4>A randomized, double blind, placebo-controlled clinical trial of favipiravir in patients with COVID-19 pneumonia was conducted in three Spanish sites. Randomization 1:1 to favipiravir or placebo (in both groups added to the Standard of Care) was performed to treat the patients with COVID-19 pneumonia. The primary endpoint was "time to clinical improvement," measured as an improvement for ≥ two categories on a 7-point WHO ordinal scale in an up to 28 days' time frame.<h4>Results</h4>Forty-four patients were randomized (23 in the favipiravir group and 21 in the placebo group). The median time to clinical improvement was not di2024-01-01T00:00:00Z2024 Feb2025-05-18T12:52:32.415Z2025-04-19T21:04:41.016ZS-EPMC108944713840221410.1186/s41479-023-00124-6